



The Specialized and Integrated Preclinical Research Institute

Over the past decade CBSET has partnered with more than 400+ MedTech and BioTech companies, including start-ups and industry-leading corporations, enabling them to initiate clinical studies and gain subsequent US and OUS market approvals for their novel therapeutic, imaging and diagnostic technologies.

■ **CBSET is a not-for-profit research institute** headquartered in Lexington, MA, dedicated to research, education, and the advancement of early-stage biomedical technologies. CBSET's mission is to help medical device and biotechnology companies develop unique tools and new methods to promote early diagnosis of, and develop innovative treatments for, complex diseases.

■ **CBSET specializes** in the development and application of novel, minimally invasive and surgical techniques in the fields of cardiology, electrophysiology, wound healing, regenerative medicine, endoscopy/laparoscopy, orthopedics, drug and device safety, drug and device delivery, and diagnostic imaging.

■ **CBSET provides** GLP (Good Laboratory Practice) and non-GLP research services ranging from early product evaluation, through lead optimization and pre-clinical safety, to physician assessment and training. CBSET's world-class regulatory and scientific expertise helps transform early-stage concepts into novel therapies.

■ **CBSET occupies** a 40,000-square-foot, state-of-the-art facility that includes a vivarium, catheterization/imaging labs, surgical suites, dedicated labs for SEM, histopathology/pathology, and drug metabolism and pharmacokinetics. CBSET offers the latest equipment for fluoroscopy, echocardiography (TEE/TTE), electrophysiology, IVUS, optical coherence tomography (OCT), endoscopy/laparoscopy, surgical video recording, histology, microradiography, and SEM (Scanning Electron Microscopy).

■ **CBSET's professional staff** includes PhDs, DVMs and recognized experts in device and drug safety, surgery, imaging, specialized histopathology and pathology, veterinary medicine, pharmacology, lead optimization, pharmacokinetics and drug metabolism, and regulatory consulting. These individuals provide the basis for successful scientific collaborations, rapid concept advancements, unparalleled consulting services, and expert dissemination of information and findings to regulatory and scientific bodies.

CBSET has been the preclinical partner-of-choice for 400+ companies.

CBSET opened the doors to its 35,000-square-foot laboratory in November 2006. CBSET is the preclinical research leader in critically important therapeutic fields such as interventional cardiology, renal disease and dialysis, chronic drug-resistant hypertension, women's health, minimally invasive surgery, orthopaedics, biological and synthetic tissue repair, drug delivery, bioresorbable devices, combination medical devices and drug-eluting products.

CBSET's state-of-the-art facilities and equipment are an integral part to achieving regulatory success for a product. Indeed, CBSET — Concord Biomedical Sciences & Emerging Technologies — offers unparalleled GLP-compliant facilities, hospital-grade operating rooms and validated equipment to enable successful research trials of novel therapeutic, imaging and diagnostic technologies.



Peter Markham, CEO

Our mission is to help sponsors develop unique tools and new methods to promote early diagnosis of, and develop innovative treatments for, complex diseases.

MANAGEMENT TEAM

Peter M. Markham, MS
Founder, President, CEO

Haim Danenberg, MD
Chief Scientific Adviser

John Keating, DVM, DACVP
Director, Pathology

Brett G. Zani, PhD
Director, Applied Sciences

Misty J. Williams-Fritze, DVM
Director, Veterinary Services

Rose Baird, MS, MBA
Director, Business & Technical Operations

Lynn Bailey, AS, LATG
Director, Interventional Services

Michael Naimark, MS
Director, Business Development

Rami Tzafirri, PhD
Principal Scientist

BOARD OF DIRECTORS

Elazer Edelman, MD, PhD (Chair)
Harvard-MIT Biomedical Eng. Center

Peter M. Markham
CEO, CBSET

Adam Groothuis, PhD
VP, Medical Affairs, Mitralign

Campbell Rogers, MD
CMO, HeartFlow

Here's what some Sponsors are saying about CBSET...

We chose to partner with CBSET because they can provide expert research support for all phases of biomedical discovery and development research.

Ray Cohen, Vessix Vascular

As a European company, we were very impressed with CBSET's expertise and willingness to work as a team to satisfy the requirements of GLP safety and efficacy studies from start to finish.

Barry Russell, neoSurgical